Pfizer (PFE), BioNTech SE (BNTX) Say Three Vaccine Doses Neutralize Omicron Variant - DJ

(Updated - December 8, 2021 6:53 AM EST)

Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) said a third dose of their vaccine neutralized Omicron in lab tests, according to Dow Jones.

The two-dose regimen was significantly less effective.

A third dose increased antibodies 25-fold compared to two doses in the variant. Two doses may prove effective in preventing severe illness.

You May Also Be Interested In

• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• FDA aligns with Regenxbio on path to refile MPS II gene therapy BLA
• Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer